During severe acute respiratory distress syndrome (ARDS), pulmonary hypertension occurs due to obliteration of the pulmonary capillary bed and together with microvascular vasoconstriction, may lead to right ventricular failure 1 . This is a relatively frequent complication of the disease 2 . Inhaled nitric oxide (iNO) may improve oxygenation, reduce pulmonary artery pressure and improve right heart performance 3 . phosphodiesterase (PDE-1) has recently been reported to enhance iNO pulmonary vasodilation effect for a short period in infants after cardiac surgery 4 and in ARDS 5 . No data are available on the prolonged use of PDE inhibitors in adult critically ill patients, although ample literature is now available on chronically ill subjects with pulmonary hypertension 6 . by the FDA for erectile dysfunction. It did not show 7 and the onset and the duration of the two drugs are in patients with prolonged Q-T, although no severe adverse effects have been reported so far. Subsequent studies focused on its potential use in pulmonary PDE-1 8 .
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by the FDA for erectile dysfunction. It did not show 7 and the onset and the duration of the two drugs are in patients with prolonged Q-T, although no severe adverse effects have been reported so far. Subsequent studies focused on its potential use in pulmonary PDE-1 8 .
There is little data supporting the enteral use of any kind of PDE-1 for the treatment of refractory pulmonary hypertension in the critical care setting. We report a case of right ventricular failure in ARDS due to pulmonary hypertension, in which weaning from iNO and from mechanical ventilation was possible
CASE HISTORY
After seven days of bilateral pnemococcal pneumonia, a 66-year-old woman with septic shock was admitted to our intensive care unit (ICU). She was a heavy smoker with a clinical history of recurrent bronchitis. A CT scan showed bilateral lung consolidation. The P a O 2 /FiO 2 ratio was 97 with 12 cmH 2 O positive end expiratory pressure and the total static lung compliance was 37 ml/cmH 2 O. Fluids and inotropic support (dobutamine and noradrenaline) resulted in cardiac index (CI) 2.9 l/min/m 2 , global end-diastolic volume 859 ml/m 2 and intrathoracic blood volume 1363 ml/m 2 , measured using continuous cardiac output with the PiCCO system SUMMARY We report a 66-year-old patient with refractory pulmonary hypertension secondary to ARDS who was being treated with inhaled nitric oxide. Enteral vardenafil (phosphodiesterase-5 inhibitor) was tried at two different doses (10 mg and 5 mg), in order to wean the patient from nitric oxide. The higher dose decreased pulmonary pressure but caused systemic hypotension and the drug was discontinued. Subsequently, a 5 mg dose of vardenafil decreased pulmonary pressure without hypotension. Pulmonary hypertension was controlled using vardenafil 10-15 mg divided in 2-3 daily doses. This therapy allowed nitric oxide withdrawal, weaning from mechanical ventilation and discharge from ICU.
Vardenafil acted in synergy with inhaled nitric oxide, permitted nitric oxide reduction and discontinuation and proved to be effective as a single, long-term treatment for pulmonary hypertension.
(Pulsion Medical System, Munich, Germany). After 36 hours of treatment, an echocardiogram showed right ventricular distension with signs of incipient failure: right atrial area was 26 cm 2 (normal values are considered up to 19.5 cm 2 ), medium-lateral diameter was 40 mm (normal values average 22-36 mm on systolic contraction), tricuspid annular plane systolic excursion (TAPSE) was 10 mm ( normal values is more than 14 mm) and the foramen ovale was closed.
A pulmonary artery catheter was then introduced to monitor pulmonary pressures: pulmonary artery pressure (PAP) was 49/26 mmHg, mean 34 mmHg; mean occlusion pressure-(PAOP) was 13 mmHg and mixed venous saturation 73.7%.
Inhaled NO commenced on the second day (10 ppm), improved the P a O 2 /FiO 2 ratio to 145, decreased PAP to 40/20 mmHg, mean 26 mmHg with a PAOP of 12 mmHg and was associated with a rise of CI to 3.6 l/min/m 2 .
In the following days shunt fraction decreased allowing iNO suspension on day 16. Afterwards, although gas exchange remained stable, echocardiography showed a progressive increase in pulmonary hypertension. On day 30 we found a systolic PAP of 62 mmHg, an apparent remodelling of the right ventricle (medium-lateral diameter 44 mm) with signs of reduced right ventricular function (diffuse the right atrium (area 28.4 cm 2 ). Rescue iNO (15-20 ppm) and dobutamine were administered again to restore an adequate CI (3.3 l/min/m 2 ).
Twenty-four hours after re-starting iNO, we tested pH (permissive hypercapnia and protective lung reduced dose (5 mg) was tried again. The peak effect was reached within 90 minutes and lasted for six hours (Table 1) . Figure 1 shows a comparison between two echocardiograhic examinations in apical fourchamber view. The right atrium, left atrium, right and the left ventricle are visualised. A slight reduction of right atrial dimension can be observed one hour after 15 mg, in two or three divided doses and according to systemic pressure, was then prescribed, resulting in haemodynamic (decreased PAP, reduced dimensions of right ventricle and right atrium) and respiratory improvement: the P/F ratio increased from 97 to steadily in the following days ( Table 2 ). Inhaled NO was suspended on day 78. After 156 days of ICU stay, the patient was transferred to another hospital for rehabilitation with minimal respiratory assistance and DISCUSSION ARDS may lead to pulmonary hypertension and right ventricular failure 9 . While in the vast majority of cases pulmonary hypertension reverses as the patient's status improves, in the present report it was the main obstacle to the weaning.
Inhaled NO induces pulmonary vasodilation, decreases right ventricular afterload without systemic hypotension and reverses hypoxic pulmonary vasoconstriction 5,9 . Unfortunately, whenever iNO was withdrawn from our patient, pulmonary hypertension and right ventricular dysfunction recurred. This pattern has been recently reported 10 .
In this scenario, the enteral use of the PDE-5 iNO, which subsequently allowed iNO withdrawal.
term treatment in reducing pulmonary hypertension and allowing weaning 5,9 . (Tables 1 and 2, Figure 1. 
